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Currently available data on prognostic implication of additional neoplasms in GIST miss comprehensive
information on patient outcomewith regard to overall or disease specific and disease free survival. Registry data of
GIST patients with and without additional neoplasm were compared in retrospective case series. We investigated
a total of 836 patients from the multi-center Ulmer GIST registry. Additionally, a second cohort encompassing 143
consecutively recruited patients of a single oncology center were analyzed. The frequency of additional malignant
neoplasms in GIST patients was 31.9% and 42.0% in both cohorts with amean follow-up time of 54 and 65months
(median 48 and 60 months), respectively. The spectrum of additional neoplasms in both cohorts encompasses
gastrointestinal tumors (43.5%), uro-genital and breast cancers (34.1%), hematological malignancies (7.3%), skin
cancer (7.3%) and others. Additional neoplasms have had a significant impact on patient outcome. The five year
overall survival in GIST with additional malignant neoplasms (n= 267) was 62.8% compared to 83.4% in patients
without other tumors (n = 569) (P b .001, HR=0.397, 95% CI: 0.298-0.530). Five-year disease specific survival
was not different between both groups (90.8% versus 90.9%). 34.2% of all deaths (n = 66 of n = 193) were
GIST-related. The presented data suggest a close association between the duration of follow-up and the rate of
additional malignancies in GIST patients. Moreover the data indicate a strong impact of additional malignantwriting of the report. The authors have no conflict of interest or financial disclosure
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be warranted.
Neoplasia (2015) 17, 134–140Introduction
Gastrointestinal stromal tumors (GIST) are the most common primary
mesenchymal neoplasms of the gastrointestinal tract with an incidence of
7 to 20 permillion [1–6]. Predominant locations are the stomach (60% to
-70%) and small intestine (25% to 30%), less common sites are the large
bowel (up to 5%) and the omentum/mesentery (up to 5%) [7,8]. Key
event of pathogenesis inGIST are gain of functionmutations in the genes
encoding the receptor tyrosine kinase KIT (80% to 90%) or platelet
derived growth factor receptor α (PDGFRα) (5% to 10%) [9–11].
Prognosis of GIST and patient outcome is based on tumor size, mitotic
rate and tumor location [12–16]. Complete surgical resection is the
primary and the only curative treatment for local GIST. Adjuvant therapy
of the tyrosine kinase inhibitor (TKI) imatinib is recommended in high
and intermediate risk GIST [17]. TKI application remains the treatment
of choice for non-resectable GIST or metastatic disease either in the
neo-adjuvant or primary setting [18,19]. Clinical presentation of GIST
is variable. Abdominal pain or discomfort, palpable abdominal mass or
gastrointestinal hemorrhage are the mainly reported symptoms, mostly
related to tumorsite. About 20% to 30% of GISTs are asymptomatic
and therefore diagnosed incidentally (e.g. during surgical procedures for
other diseases [8]).
GIST are reported to occur in association with other secondary
neoplasms at rates of 14% to 25% [20–25]. The spectrum of additional
malignancies varies among themost common cancers, such as colorectal
cancer, prostate cancer, breast cancer and gastric cancer. However, there
are also reports on additional neoplasms like hematological germ cell
and neuroendocrine tumors [20–25]. So far data are limited on the
impact of secondary neoplasms on GIST prognosis and/or patient
outcome. The largest study including 783 patients of one institutional
tumor registry reported a rate of secondary neoplasms in 20% [22]. In
contrast, very recently 43% of secondary neoplasms have been reported
of a GIST cohort including only 86 patients [26]. Systematic work is
missing regarding patient outcome and the assessment of overall survival
(OS), disease specific survival (DSS) and disease free survival.
Therefore, the aim of the present study was to elucidate
comprehensively the frequency and the type of additional neoplasms
in a large-scale cohort of patients with GIST with focus on disease
prognosis and patient outcome.
Patients and Methods
Patients
This study included 836 patients with histologically confirmed
diagnosis of GIST from the multi-center Ulmer GIST Registry from
2006 to 2011. These patients were registered in a multi-center
network encompassing 18 oncological centers in South Germany,
according to the User’s Guide to Registries Evaluating Patient
Outcomes and to the Strengthening (of) the Reporting ofObservational
Studies inEpidemiology (STROBE) Statement [27–31]. All cooperating
centers are non restricted, open hospitals implicating neither demo-graphic nor social or clinical selection bias. Patients diagnosed before
2006 were registered retrospectively. Since 2006 registration and follow
up was intended to be prospectively. After obtaining patients’ consent
descriptive and clinical data were collected from medical records, by a
personal patient contact and/or contact with the treating physicians.
Patients with a multineoplastic syndrome (i.e. Carney triad, type 1
neurofibromatosis/NF-1, familial GIST etc.) were not included.
The following clinicopathological parameters have been assessed:
age, gender, clinical manifestation, tumor localization, primary size,
mitotic rate, risk classification according to Fletcher et al. [12],
Miettinen et al. [16] and Joensuu et al. [15], histological subtype,
immunohistochemical staining (KIT in all cases; other markers if
available), treatment (surgical resection, extent of resection, TKI
application). Main attention was focused on the occurrence of
additional neoplasms (benign and/or malign) i.e. GIST patients with
multiple tumors as well as secondary malignancies. Outcome
measurements were metastases, tumor recurrence and death (GIST
related or not). The patients were divided into two main groups:
GIST patients with and without additional neoplasms. In order to
ascertain center specific differences as selection bias, data from the
single oncology center of the University Hospital of Ulm were
compared with data from the multicenter Ulmer GIST registry.
The study was approved by the institutional ethics committee and all
patients gave written informed consent (Study No.: 90 + 91/2006).
Statistical Analyses
Patient characteristics between the groups were compared by χ2 or
Fishers exact test. Estimates for disease-free-survival (DFS), disease-
specific-survival (DSS) and overall-survival (OS) were obtained by the
Kaplan-Meier method [32] and differences between Kaplan-Meier
curves were investigated by the log-rank test (after Mantel-Cox or
Breslow-test, respectively). For analyses of disease-specific survival, non
GIST-related deaths were censored. If applicable, the Hazard Ratio
(HR) and 95% confidence interval (95% CI) were calculated regarding
tumor-related death and tumor recurrence and/or metastasis by
applying univariate Cox proportional hazards regression models. To
prove the most relevant findings of the univariate model and Kaplan-
Meier analyses, an additional multivariate Cox proportional hazards
regression model has been established considering the variables age,
gender, mitotic rate, tumor size and location. Statistical analysis was
performed using SPSS V19.0 (SPSS Inc., USA). A value of α b .05 was
considered to be significant.
Results
Descriptive and clinical data for both cohorts are given in Table 1. 836
GIST patients with a median age of 67.9 years (range 24.5-94.8 years)
and a female to male ratio of 1:1 were included in all analyses. Most
tumors were localized in the stomach (63.7%) followed by the small
bowel (28.8%), and other tissues (7.5%) including colorectal (4.7%)
and extra-gastrointestinal (1.5%) GIST. The most common clinical
Table 1. Demographic and Clinicopathological Data of 836 GIST Patients with Additional Neoplasms
Parameter Single center (n = 143) Multi center (n = 836)
Epidemiology (N) % (N) %
Gender (male vs. female) (70/73) 49.0/51.0 (423/413) 50.6/49.6
Mean age at diagnosis (year ± S.D.) 64.7 (12.7) 66.3 (12.3)
Median age at diagnosis (year, range) 66.7 (24.5; 94.1) 67.9 (24.5; 94.8)
Localisation of GIST
Gaster/small bowel/other (84/48/9) 59.6/34.0/6.4 (519/235/61) 63.7/28.8/7.5
Pathological parameters
Cell morphology (spindle vs. epithelioid/mixed) (116/13) 89.9/10.1 (618/125) 83.2/16.8
Mean tumor size (cm) 6.0 (5.6) 5.4 (4.7)
Median tumor size (cm) 4.4 (0.4; 40.0) 4.1 (0.3; 40)
Mitotic rate (b5 vs. ≥5/50 HPF) (73/39) 65.2/34.8 (421/178) 70.3/29.7
Mitotic rate (b10 vs. ≥10/50 HPF) (92/20) 82.1/17.9 (497/100) 83.2/16.8
IHC KIT (pos vs. neg) (128/2) 97.7/2.3 (743/17) 97.8/2.2
IHC CD34 (pos vs. neg) (98/21) 82.4/17.6 (544/73) 88.2/11.8
Risk classification
NIH (high/intermediate/low/very low) (38/21/39/25) 30.9/17.1/31.7/20.3 (173/145/219/115) 26.5/22.2/33.6/17.6
AFIP (high/intermediate/low/very low) (32/8/50/27) 27.4/6.8/42.7/23.1 (135/83/269/140) 21.5/13.2/42.9/22.3
mod. NIH (high/intermediate/low/very low) (40/19/37/27) 32.5/15.4/30.1/22.0 (211/107/195/140) 32.3/16.4/29.9/21.4
Clinical parameters
Resection (R0 vs. R1/2) (106/10) 91.4/8.6 (631/48) 92.9/7.1
Multivisceral resections (yes vs. no) (31/112) 21.5/78.5 (194/642) 23.2/76.8
TKI-Therapy (yes vs. no) (23/109) 19.7/80.3 (150/568) 20.9/79.1
Incidental diagnosis (yes vs. no) (51/79) 39.2/60.8 (307/465) 39.8/60.2
Secondary neoplasms
Rate of malignant neoplasms (60) 42.0 (267) 31.9
Rate of benign neoplasms (30) 21.0 (209) 25.0
Rate of malignant or benign neoplasms (81) 56.6 (422) 50.5
Rate of multiple malignant NPL (11) 7.6 (45) 5.3
Symptoms
Abdominal pain (44) 46.8 (172) 21.9
GI bleeding (39) 41.5 (167) 21.2
Weight loss (15) 16.0 (45) 5.7
Survival analysis
Mean follow-up time (year ± SD) 5.4 (3.9) 4.5 (3.5)
Median follow-up time (year, range) 5.0 [0.01; 18.5] 4.0 [0.01; 23.2]
Death (total/GIST-related) (41/15) 28.7/10.5 (193/66) 23.1/7.9
Rate of recurrence or metastases (30 of 135) 22.1 (146 of 761) 19.2
Overall-survival-rates (1-/3-/5-year) (121/93/69) 93.2/84.3/75.4 (629/454/300) 92.3/84.0/76.6
Disease-specific survival-rates (1-/3-/5-year) (121/93/69) 97.6/93.1/88.7 (629/454/300) 97.3/94.3/90.9
Disease-free-survival rates (1-/3-/5-year) (105/77/57) 86.4/80.9/78.5 (526/366/239) 88.9/84.8/81.9
SD, standard deviation; GI, gastrointestinal; TKI, tyrosine kinase inhibitor; IHC, immunohistochemistry.
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intestinal bleeding (21.2%) and weight loss (5.7%). 39.2% had no
clinical symptoms and the GISTs were detected incidentally. Surgical
resectionwas performed in 98%withR0 resection in 92.9%of patients.
TKI treatment was used in 20.9% of GIST.Major cell morphology was
spindle cell (83.2%), 16.8% showed a mixed or epithelioid pattern.
Mean and median tumor size was 5.4 cm (±SD 4.7 cm) and 4.1 cm
(0.3-40 cm). 16.8% and 70.3% of tumors showed a mitotic rate of
≥10/50 high power fields (HPF) and b5/50HPF, respectively. KIT
staining was positive in 97.8%. Risk classifications according to Fletcher
et al. [12] and Joensuu [15] (modified NIH-classification) resulted in
high risk patients in 26.5% and 32.3%, respectively and in
intermediate/low risk patients in 73.4% and 67.7%, respectively.
Outcome Measurements
Metastases or tumor recurrence occurred in 19.2% (n = 146 of 761
patients), while 11.2% (93 of 836 pts) of GIST patients had initial
metastases. Median follow up-time until tumor recurrence or metastases
in high-risk patients was 2.75 years (range 0.12; 22.6 yrs). 23.1%
(n = 193) patients died, 66 of them (34.2%) due toGIST-related causes.
1-, 3- and 5-year OS were 92.3%, 84.0% and 76.6%, respectively.
The 1-, 3- and 5-year DSS was 97.3%, 94.3% and 90.9%,
respectively. The 1-, 3- and 5-year DFS was 88.9%, 84.8% and81.9%, respectively. Five-year patient outcome for high risk versus
non-high risk patients of the Ulmer multicenter registry was
significantly reduced with a DSS of 78.4% vs. 95.8% (HR=7.17,
CI 95% 3.56-14.45, P b .001) and a DFS of 50.0% vs. 93.8%
(HR = 9.54, 95% CI 5.82-15.62, P b .001). OS was not different
between both groups (71.8% vs. 80.8%).
GIST and Additional Malignancies
In the Ulmer GIST registry (n = 836) additional neoplasms
associated with GIST were found in 50.5% (422 patients with 579
malign and/or benign tumors; Table 1). A total of 31.9 % of GIST
showed malignant tumors (317 tumors in 267 patients). The median
follow-up time was 4.0 years (range 0.01-23.2 years). In the single
center cohort a total of 56.6% GIST patients showed additional
neoplasms. Malignancies in addition to GIST occurred in 42.0%
(60 of 143 patients with 73 tumors). The median follow-up time was
5.0 years (range 0.01 to 18.5 yrs). The detailed spectrum of additional
secondary malignacies is given in Table 2. Fourty-five GIST patients
(5.3%) were affected by two or more tumors (Supplemental Table 1).
Three of those patients had three and one patient even four malignant
cancers. Detailed information of additional benign tumors are given
in the Supplemental Table 2). Comparative analyses between both
cohorts (single versus multi-center GIST cohort) showed no
Figure 1. Overall survival in comparison of GIST patients with and
without secondary malignancies.
Table 2. Type and Frequency of Secondary Malignancies in Patients With GIST
Present study 2014 Pandungeran et al.
2010
Agaimy et al. 2006
n (N) % (N) % (N) %
GI-cancers (138) 43.5 (48) 25.8 (228) 46.9
Colorectal (68) 21.5 (18) 9.7 (109) 22.4
Rectal cancer 22
Colon cancer 46
HBP NPL (20) 6.3 (8) 4.3 (20) 4.1
Pancreas Cancer 15
Gallbladder 2
IPMN 1
Cholangio carcinoma 1
Ampullary cancer 1
Esophagus and stomach (44) 13.9 (14) 7.5 (106) 21.8
Stomach cancer 33
Esophagus cancer 11
Other GI Ca (6)
Neuroendocrine-cancer 4
Duodenal cancer 1
Jejunal cancer 1
Urological, gynaecologoical and
breast cancer
(108) 34.1 (77) 41 (129) 29
Gynaecological tumor (61) 19.2
Prostate cancer 38
Uterus cancer 12
Cervix cancer 4
Ovarian cancer 4
Uterus leiomyosarcoma 2
Seminoma 1
Urological cancer (21) 6.6 (18) 9.7 (37) 7.6
Renal cell cancer 12
Urothelial cancer 9
Breast cancer (26) 8.2 (15) 8.1 (34) 7.0
Blood-NPL (23) 7.3 (12) 6.5 (37) 7.6
Multiple myeloma 7
Lymphoma 7
Chronic lymphatic leucemia 5
Acute myeloid leucemia 1
Poly cythemia vera 2
Hairy cell leukemia 1
Skin tumors (23) 7.3 (9) 4.8 (13) 2.7
Squamous carcinoma 10
Malignant melanoma 8
others 5
Lung tumors (8) 2.5 (10) 5.4 (26) 5.4
Lung cancer 7
Carcinoid 1
others (17) 5.4 (31) 16.6 (49) 10.1
Pheochromocytoma 3
Thyroid cancer 3
CUP 2
Larynx cancer 2
Oral cancer 2
Malignant paraganglioma 1
Osteosarcoma 1
Leiomyosarcoma 1
Glomus tumor (malignant) 1
Uvea melanoma 1
(n = 295 own pts.)
(n = 191 literature)
Total (n = 317) 100% (n = 186) 100% (n = 486) 100%
IPMN, Intraductal papillary mucinous neoplasm; CUP, Carcinoma of unknown primary.
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location, tumor size, mitotic rate, histological subtype, KIT positivity,
resection extent and rate of TKI-application; Table 1).
Outcome of GIST With and Without Additional Malignancies
The OS after 5 years in GIST patients with and without secondary
malignancies was 62.8% and 83.4%, respectively indicating a
significant difference (P b .001 log-rank; P b .001 Cox model, HR0.397, 95% CI: 0.298-0.530; Figure 1, Tables 3 and 4). Data
regarding 5 year DSS were not different between both groups (90.8%
and 90.9%, Figure 2, Tables 3 and 4). The median survival time in
GIST patients with and without secondary malignancies was 7.4 years
(range 5.9-8.8) and 14.8 years (range 10.3-19.3), respectively.
Detailed results are shown in Table 3.
Discussion
In 2000, at the first time Maiorana et al. reported on a small series of
epithelioid gastric GIST associated with additional neoplasms [33].
Kalmár et al. concluded a significantly higher secondary neoplasia rate
in GIST in comparison to a Hungarian control population (21.7% vs
4%; P b .001) based on 5 from 23 GIST patients with secondary
malignancies and a follow-up time of 1–157 month. Mean age as well
as the male to female ratio was similar in both groups [34]. Ruka et al.
reported on 18 patients (10.0%) with a history of other malignancies
among 180 GIST patients with a median age of 60 years whereby two
GIST patients suffered from more than one other tumor [35]. In the
same year Kövér et al. emphasized the high association of GIST with
additional neoplasms, reporting of 7 from 43 GIST patients (16.3%)
with secondary malignancies [36]. Agaimy et al. described 18.6% of
GIST occurring secondary neoplasms (18/97 cases) with a female to
male ratio of 2:1. GIST showed a trend towards small size (only 2 vs
18 large GIST), the majority of associated malignancies (50%) were
classified as GI-cancers [37]. In 2006, Wronski et al. described a 14%
rate of secondary neoplasms in GIST in 4/28 GIST patients [38]. A
review of the literature and own cases by Agaimy et al. revealed 518
cancers in 486 GIST patients among a total of 4813 patients,
accounting for secondary neoplasias and multiple neoplasias in 10.1%
and 0.6% of GIST patients, respectively [20]. In the literature the
reported frequency of additional neoplasms in GIST patients varies by
4.5% to 33% (mean 13%), and about half of them (47%) accounted
for GI-cancers, followed by urogenital tumors. In the series of Liszka
et al. 2007, 17 of 82 patients presented with secondary malignant
Table 3. Comparison of GIST Patients With and Without Second Malignancies
Parameter (n = 267) With 2nd malignancies (n = 569) without 2nd malignancy P value, (− test)
(N) % (N) %
Epidemiology
Gender (male vs. female) (148/119) 55.4/44.6 n = 294/n = 275 48.3/51.7% P = .0561)
Mean age at diagnosis (year, (±SD) 69.3a (10.6) 64.9 (12.9) P b .0012)
Median age at diagnosis (year, [range]) 69.7 [36.8; 94.8] 66.5 [24.5; 93.3] -
Localisation of GIST
Gaster/Small bowel/Other (172/72/21) 64.9/27.2/7.9 (347/163/40) 63.1/29.6/7.3 -
Pathological Parameters
Cell morphology (spindle vs. epithelioid/mixed) (198/31) 86.5/13.5 (420/94) 81.7/18.3 P = .1101)
Mean tumor size (cm, ±SD) 4.1 (3.8) 5.9 (5.0) P b .0012)
Median tumor size (cm, [range]) 3.0 [0.03; 20.0] 4.9 [0.2; 40.0] -
Mitotic rate (b5 vs. ≥5/50 HPF) (136/45) 75.1/24.9 (285/133) 68.2/31.8 P = .0871)
Mitotic rate (b10 vs. ≥10/50 HPF) (153/27) 85.0/15.0 (344/73) 82.5/17.5 P = .4521)
IHC KIT (pos vs. neg) (237/3) 98.8/1.3 (506/14) 97.3/2.70 P = .2111)
IHC CD34 (pos vs. neg) (175/19) 90.2/9.8 (369/54) 87.2/12.8 P = .2891)
Risk Classification
NIH (high vs. Non-high risk) (41/162) 20.2/79.8 (132/449) 29.4/70.6 P = .0141)
AFIP (high vs. Non-high risk) (32/163) 16.4/83.6 (103/329) 23.8/76.2 P = .0141)
mod. NIH (high vs. Non-high risk) (52/151) 25.6/74.4 (159/291) 35,3/64.7 P = .0141)
Clinical parameters
Resection (R0 vs. R1/2) (198/13) 93.8/6.2 (433/35) 92.5/7.5 P = .5351)
TKI-Therapy (yes vs. no) (34/189) 15.2/84.8 (116/379) 23.4/76.6 P = .0131)
Incidental diagnosis (yes vs. no) (147/98) 60.0/40.0 (160/367) 30.4/69.6 P b .0011)
Survival analysis
Mean follow-up time (year, (±SD) 4.0 (±3.2) 4.7 (±3.6) P = .0162)
Median follow-up time (year, [range]) 3.5 [0.01; 18.5] 4.2 [0.01; 23.2] -
Death (GIST-related vs. not) (19/98) 7.1/36.7 (47/95) 8.3/16.7 -
Rate of recurrence or metastases (38) 16.8 (99) 20,2 P = .2781)
Overall-survival-rates (1-/3-/5-year) (194/135/88) 88.5/75.0/62.8 (435/319/212) 94.0/88.3/83.4 P b .0013)
Disease-specific survival (1-/3-/5-year) (194/135/88) 99.0/96.5/90.8 (435/319/212) 96.6/93.4/90.9 P = .6033)
Disease-free survival (1-/3-/5-year) (159/108/66) 90.7/88.1/82.7 (367/258/173) 88.1/83.4/81.5 P = .5863)
1) χ2-test, 2) t test, 3) log-rank test.
138 GIST and additional neoplasms Kramer et al. Neoplasia Vol. 17, No. 1, 2015neoplasia (20.7%) and a trend towards a small intestinal manifesta-
tion was found [21]. Focusing on immune-histochemical and
mutational analysis, Arnogiannaki et al. 2010 reported no differences
between GIST patients with (6 of 20 GIST) or without additional
malignancy [39]. The largest clinical study, including 783 GIST
patients, reports on 153 patients (20.3%) with additional malignan-
cies [22]. Of interest 15.7% (n = 24/153) presented with
synchronous and 84.3% (n = 129/153) with metachronous
malignant neoplasms. A total of 20.9% GIST (n = 32/153) developedTable 4. Comparative Survival Analyses of GIST Patients With andWithout Secondary Malignancies
(Ntotal= 267/569) With
2nd NPL
Without
2nd NPL
Univariate Cox
model
Multivariate Cox
model
% (N) % (N) P, HR (95% CI) P, HR (95% CI)
Disease-specific-survival
1-year DSS 99.0 (194) 96.6 (435) P = .603, HR 1.164
(0.657;2.061)
P = .880, HR 1.053
(0.536;2.070)3-year DSS 96.5 (135) 93.4 (319)
5-year DSS 90.8 (88) 90.9 (212)
Overall-survival
1-year OS 88.5 (194) 94.0 (435) P b .001HR 0.397
(0.298;0.530)
P b .001 HR 0.402
(0.282;0.575)3-year OS 75.0 (135) 88.3 (319)
5-year OS 62.8 (88) 83.4 (212)
Disease-free survival
1-year DFS 90.7 (159) 88.1 (367) P = .586 HR 1.118
(0.748;1.672)
P = .616 HR 0.883
(0.544;1.435)3-year DFS 88.1 (108) 83.4 (258)
5-year DFS 82.7 (66) 81.5 (173)
DSS, disease specific survival; DSF, disease free survival; OS, overall survival; HR, hazard ratio.
Multivariate Cox proportional hazards regression model has been adjusted considering the variables age,
gender, mitotic rate, tumor size and localization (GIST).secondary malignancies (after the diagnosis of GIST) and 63.4%
(n = 97/153) have had a history of previous malignancies however,
without impact on the prognosis of GIST.Figure 2. Disease specific survival in GIST patients with and without
secondary malignancy.
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neoplasms in GIST miss comprehensive information on patient
outcome with regard to overall or disease specific and disease free
survival. Therefore the present study, focused on the prognostic
impact of additional neoplasms in GIST, investigating a large-scale
multicenter cohort of 836 patients with GIST and in addition a
single-center cohort of 143 GIST patients.
We observed 31.9% and 42.0% of GIST associated with additional
malignancies by mean follow-up times of 4.5 years and 5.4 years,
respectively. As expected the duration of the follow-up time was closely
linked to the occurrence of secondary malignancies in GIST. In
accordance with other studies, type of secondary malignancies
encompasses the most common cancer entities such as GI cancers
(43.5%) and urogenital and breast cancers (34.1%). Of note lung
cancer (2.5%) was remarkable underrepresented [20–22,26]. Within
the three largest studies, themajority (75% to 80%) of GIST-associated
tumors are gastrointestinal (25.8% to 46.6%) as well as urogenital and
breast cancer (29% to 41%) [20,22] (Table 2).
The impact on prognosis of secondary malignancies is indicated by
a significantly reduced five year OS rate of 62.8% compared to 83.4%
in GIST patients without associated malignancies (P b .001 log rank;
P b .001 Cox model, HR 0.397, 95% CI: 0.298; 0.530; Figure 1,
Tables 3 and 4). Five year DSS rates were identical (90.8% and
90.9%), demonstrating the importance of comprehensive outcome
measures (e.g. OS vs DSS) in cancer patients.
Most GISTs associated additional malignancies occurred in
patients who are 5 to 10 years older (P b .001, t test) and they
tend to fall into the low or very low risk category (P = .002, χ2-test),
which is in accordance with the published data [20–22,26]. The rate
and spectrum of additional neoplasms (5% to 43%), the male to
female ratio (58.3% males: 41.6% females to 42.1% males: 59.9%
females) as well as the impact of second malignancies on the
prognosis of GIST (none to significant) varies among several studies
according to study size, duration of follow-up and comprehensive-
ness of survival analysis [20–23,26,33,36,38]. These differences may
also arise due to referral bias, different durations of follow up, study
designs and comprehensiveness of survival analysis or simply due to
different populations.
In accordance with Vassos et al. [26], the presented data confirm
the major impact of GIST-associated malignancies on the prognosis
of GIST and underpins the relevance of comprehensive outcome
measurements. With regard to the 10 year survival probability,
indicating an almost 50% difference between OS (38.4%) and DSS
(86.8%) in the present study, we suggest a regular and continuous
follow up of GIST patients at least for 10 years. Currently,
pathophysiological mechanisms explaining the high risk of GIST
patients for secondary malignancies are unknown which needs
systematic basic as well as clinical research activities for the future.
Moreover treatment strategies like the adjuvant TKI use in GIST may
benefit from such kind of knowledge both for the selection of right
patient and clinical outcome.
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